GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » EV-to-FCF

PRTG (Portage Biotech) EV-to-FCF : -0.17 (As of Dec. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Portage Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Portage Biotech's Enterprise Value is $1.63 Mil. Portage Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.80 Mil. Therefore, Portage Biotech's EV-to-FCF for today is -0.17.

The historical rank and industry rank for Portage Biotech's EV-to-FCF or its related term are showing as below:

PRTG' s EV-to-FCF Range Over the Past 10 Years
Min: -1.26   Med: 5.21   Max: 35.84
Current: -0.17

During the past 13 years, the highest EV-to-FCF of Portage Biotech was 35.84. The lowest was -1.26. And the median was 5.21.

PRTG's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs PRTG: -0.17

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-16), Portage Biotech's stock price is $3.00. Portage Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-94.660. Therefore, Portage Biotech's PE Ratio (TTM) for today is At Loss.


Portage Biotech EV-to-FCF Historical Data

The historical data trend for Portage Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech EV-to-FCF Chart

Portage Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.26 -89.44 -16.05 -3.58 -0.38

Portage Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -1.91 -0.38 -0.04 -0.51

Competitive Comparison of Portage Biotech's EV-to-FCF

For the Biotechnology subindustry, Portage Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portage Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Portage Biotech's EV-to-FCF falls into.



Portage Biotech EV-to-FCF Calculation

Portage Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.627/-9.798
=-0.17

Portage Biotech's current Enterprise Value is $1.63 Mil.
Portage Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Portage Biotech  (NAS:PRTG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Portage Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.00/-94.660
=At Loss

Portage Biotech's share price for today is $3.00.
Portage Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.660.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Portage Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Portage Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Portage Biotech Business Description

Traded in Other Exchanges
N/A
Address
Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.